Literature DB >> 11692053

Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study.

E Cuillerier1, M Lémann, Y Bouhnik, M Allez, J C Rambaud, R Modigliani.   

Abstract

BACKGROUND: The efficacy of azathioprine (AZA) in chronically active Crohn's disease (CD) is well established. Whether this drug is also useful to prevent recurrences after surgery is unknown. We report here our experience of AZA in this therapeutic goal.
METHODS: Between 1987 and 1996, 38 patients with CD were treated with AZA to prevent postoperative recurrence. Twenty-three of these had undergone a curative resection with removal of all previously involved parts of the gut. In the other 15 patients, resection was limited to the parts of the gut macroscopically abnormal at the time of surgery; those parts that were previously involved but normal at this time were conserved. The operative procedures were ileocolonic resection (n = 18), subtotal colectomy with ileorectal anastomosis (n = 12), coloproctectomy with ileo-anal anastomosis (n = 4) or ileostomy (n = 2), ileal resection (n = 1) and segmental colectomy (n = 1). Twelve patients had been treated previously with AZA before surgery; in 26 patients, AZA was started within the 2 months following surgery.
RESULTS: The median duration of postoperative follow-up was 29 months. Probabilities of clinical recurrence according to the Kaplan-Meier method were 9, 16 and 28% at 1, 2 and 3 years, respectively. For the 25 patients who had a colonoscopy or a small bowel barium X-ray during the follow-up, probabilities of anatomical recurrence were 16, 36 and 59% at 1, 2 and 3 years, respectively. The probability of anatomical recurrence was significantly higher in patients who had segments of the gut previously involved but not removed because they were macroscopically normal at the time of surgery.
CONCLUSION: In patients treated with AZA, the rate of postoperative endoscopic recurrence was lower than that previously reported in untreated patients. Our results suggest that AZA should be evaluated prospectively for prevention of postoperative CD recurrence, at least in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11692053     DOI: 10.1097/00042737-200111000-00005

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

Review 1.  Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field.

Authors:  Anna M Borowiec; Richard N Fedorak
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

2.  European evidence based consensus on the diagnosis and management of Crohn's disease: special situations.

Authors:  R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 3.  Postoperative Crohn's disease recurrence: a practical approach.

Authors:  Pilar Nos; Eugeni Domenech
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

4.  Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients.

Authors:  Martin H Holtmann; Frank Krummenauer; Christina Claas; Kristina Kremeyer; Dirk Lorenz; Olivia Rainer; Iris Vogel; Ulrich Böcker; Stephan Böhm; Carsten Büning; Rainer Duchmann; Guido Gerken; Hans Herfarth; Norbert Lügering; Wolfgang Kruis; Max Reinshagen; Jan Schmidt; Andreas Stallmach; Jürgen Stein; Andreas Sturm; Peter R Galle; Daan W Hommes; Geert D'Haens; Paul Rutgeerts; Markus F Neurath
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

Review 5.  Maintenance of remission in Crohn's disease: current and emerging therapeutic options.

Authors:  Matthew J Brookes; Jonathon R B Green
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Surgical intervention in children with Crohn's disease.

Authors:  R Leonor; K Jacobson; V Pinsk; E Webber; D A Lemberg
Journal:  Int J Colorectal Dis       Date:  2007-02-14       Impact factor: 2.571

7.  Long-term Outcomes and Risk Factors for Reoperation After Surgical Treatment for Gastrointestinal Crohn Disease According to Anti-tumor Necrosis Factor-α Antibody Use: 35 Years of Experience at a Single Institute in Korea.

Authors:  Sang Mok Lee; Eon Chul Han; Seung-Bum Ryoo; Heung-Kwon Oh; Eun Kyung Choe; Sang Hui Moon; Joo Sung Kim; Hyun Chae Jung; Kyu Joo Park
Journal:  Ann Coloproctol       Date:  2015-08-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.